Zurich-Schlieren, April 20, 2016. At today’s Annual General Meeting of Molecular Partners AG (ticker: MOLN SW), the shareholders of the company approved all motions proposed by the Board of Directors with a large majority and elected Jeffrey H. Buchalter as new member of the Board of Directors of the company.
At today’s Annual General Assembly of Molecular Partners AG, Jeffrey H. Buchalter was elected as new member of the Board of Directors. Mr. Buchalter served in various senior executive positions, including being CEO of NASDAQ-listed Enzon (NASDAQ:ENZN) and of Ilex Oncology, as well as a Senior Executive at Pharmacia, Wyeth and Schering-Plough. He also brings experience from serving as chairman and non-executive director on various boards. He will replace Dr. Francesco De Rubertis who decided not to stand for re-election.
Jörn Aldag, Chairman of Molecular Partners commented: “We are very pleased to welcome Jeff as a new member of our Board. With his many years of strategic and operational experience in the life science industry with a focus in the commercial positioning and development of therapeutics in oncology, he will add a critical expertise to our Board.”
Jörn Aldag, Goran Ando, Steven H. Holtzman, William A. Lee, Andreas Plückthun, Petri Vainio and Christian Zahnd were all re-elected as members of the Board of Directors, and Jörn Aldag was also re-elected as Chairman of the Board of Directors of Molecular Partners AG. The proposed three members of the Compensation Committee – Jörn Aldag, William A. Lee and Petri Vainio – were also re-elected.
Further, the shareholders of Molecular Partners AG approved the annual report and the annual financial statements for the financial year 2015, as well as the appropriation of the 2015 results. The Board of Directors and the Management Board were granted discharge for the financial year 2015.
The shareholders of the company also approved the renewal of the authorized share capital for another period of two years and all proposals regarding compensation, including the proposed respective compensation amounts for the Board of Directors and the Management Board.
Financial Calendar 2016
Publication of Half-year Results 2016
September 1, 2016
Publication of Quarterly Management Statement Q3 2016
October 27, 2016
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPins. DARPins are potent, specific, and versatile small-protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.
Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors. For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.
For further details, please contact:
Dr. Christian Zahnd, CEO
Tel: +41 (0) 44 755 77 00
Andreas Emmenegger, CFO
Tel: +41 (0) 44 755 77 00
Tel: +41 (0) 43 344 42 42
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.